Is Poseida Therapeutics Stock a Good Investment?
Poseida Therapeutics Investment Advice | PSTX |
Not Rated
Examine Poseida Therapeutics Stock
Researching Poseida Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 28.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings (P/E) ratio of 214.0. Poseida Therapeutics recorded a loss per share of 0.63. The entity last dividend was issued on the June 23, 1992. The firm had 3:1 split on the April 5, 2005.
To determine if Poseida Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Poseida Therapeutics' research are outlined below:
| Poseida Therapeutics is not yet fully synchronised with the market data | |
| Poseida Therapeutics is way too risky over 90 days horizon | |
| Poseida Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 64.7 M. Net Loss for the year was (123.43 M) with loss before overhead, payroll, taxes, and interest of (21.57 M). | |
| Poseida Therapeutics currently holds about 142.56 M in cash with (92.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Poseida Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 23313 shares by Gergen Mark J of Poseida Therapeutics at 9.6 subject to Rule 16b-3 |
Poseida Therapeutics Quarterly Good Will |
|
Poseida Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Poseida Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Poseida Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Poseida Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Poseida Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-09 | 2023-09-30 | -0.29 | -0.35 | -0.06 | 20 | ||
2020-11-12 | 2020-09-30 | -0.55 | -0.63 | -0.08 | 14 | ||
2024-08-05 | 2024-06-30 | -0.41 | -0.32 | 0.09 | 21 | ||
2021-08-12 | 2021-06-30 | -0.63 | -0.74 | -0.11 | 17 | ||
2021-03-11 | 2020-12-31 | -0.69 | -0.58 | 0.11 | 15 | ||
2024-03-07 | 2023-12-31 | -0.39 | -0.27 | 0.12 | 30 | ||
2024-05-14 | 2024-03-31 | -0.42 | -0.25 | 0.17 | 40 | ||
2023-03-09 | 2022-12-31 | -0.22 | -0.39 | -0.17 | 77 |
Poseida Therapeutics Target Price Consensus
Poseida target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Poseida Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Hold |
Most Poseida analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Poseida stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Poseida Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationPoseida Therapeutics Target Price Projection
Poseida Therapeutics' current and average target prices are 9.50 and 9.50, respectively. The current price of Poseida Therapeutics is the price at which Poseida Therapeutics is currently trading. On the other hand, Poseida Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Poseida Therapeutics Market Quote on 19th of January 2025
Target Price
Analyst Consensus On Poseida Therapeutics Target Price
Poseida Therapeutics Analyst Ratings
Poseida Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Poseida Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Poseida Therapeutics' financials, market performance, and future outlook by experienced professionals. Poseida Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Poseida Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Poseida Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Poseida Therapeutics backward and forwards among themselves. Poseida Therapeutics' institutional investor refers to the entity that pools money to purchase Poseida Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 897.6 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 811.5 K | Goldman Sachs Group Inc | 2024-09-30 | 607.4 K | Charles Schwab Investment Management Inc | 2024-09-30 | 567.1 K | Northern Trust Corp | 2024-09-30 | 565.4 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 563.1 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 539 K | Woodline Partners Lp | 2024-09-30 | 478.9 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-09-30 | 359.2 K | Fmr Inc | 2024-09-30 | 14.6 M | Pentwater Capital Management Lp | 2024-09-30 | 6 M |
Poseida Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 925.93 M.Market Cap |
|
Poseida Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.58) | (0.60) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (1.37) | (1.30) |
Determining Poseida Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Poseida Therapeutics is a good buy. For example, gross profit margin measures Poseida Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Poseida Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Poseida Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Poseida Therapeutics. Check Poseida Therapeutics' Beneish M Score to see the likelihood of Poseida Therapeutics' management manipulating its earnings.
Evaluate Poseida Therapeutics' management efficiency
Poseida Therapeutics has return on total asset (ROA) of (0.1311) % which means that it has lost $0.1311 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5763) %, meaning that it created substantial loss on money invested by shareholders. Poseida Therapeutics' management efficiency ratios could be used to measure how well Poseida Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2025. Return On Capital Employed is likely to drop to -0.6 in 2025. At this time, Poseida Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.8 M in 2025, whereas Other Assets are likely to drop slightly above 1.2 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.03 | 0.71 | |
| Tangible Book Value Per Share | 0.98 | 0.61 | |
| Enterprise Value Over EBITDA | (2.84) | (2.98) | |
| Price Book Value Ratio | 3.36 | 4.84 | |
| Enterprise Value Multiple | (2.84) | (2.98) | |
| Price Fair Value | 3.36 | 4.84 | |
| Enterprise Value | 395.6 M | 545.8 M |
Understanding the operational decisions made by Poseida Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.536 |
Poseida Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Poseida Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Poseida Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Poseida Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Poseida Therapeutics' Outstanding Corporate Bonds
Poseida Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Poseida Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Poseida bonds can be classified according to their maturity, which is the date when Poseida Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View |
Understand Poseida Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Poseida Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1198 | |||
| Market Risk Adjusted Performance | (1.27) | |||
| Mean Deviation | 7.51 | |||
| Semi Deviation | 2.04 | |||
| Downside Deviation | 3.94 | |||
| Coefficient Of Variation | 759.09 | |||
| Standard Deviation | 28.3 | |||
| Variance | 801.13 | |||
| Information Ratio | 0.1307 | |||
| Jensen Alpha | 3.78 | |||
| Total Risk Alpha | 3.05 | |||
| Sortino Ratio | 0.9396 | |||
| Treynor Ratio | (1.28) | |||
| Maximum Drawdown | 230.06 | |||
| Value At Risk | (3.52) | |||
| Potential Upside | 5.14 | |||
| Downside Variance | 15.5 | |||
| Semi Variance | 4.14 | |||
| Expected Short fall | (9.24) | |||
| Skewness | 7.88 | |||
| Kurtosis | 63.34 |
| Risk Adjusted Performance | 0.1198 | |||
| Market Risk Adjusted Performance | (1.27) | |||
| Mean Deviation | 7.51 | |||
| Semi Deviation | 2.04 | |||
| Downside Deviation | 3.94 | |||
| Coefficient Of Variation | 759.09 | |||
| Standard Deviation | 28.3 | |||
| Variance | 801.13 | |||
| Information Ratio | 0.1307 | |||
| Jensen Alpha | 3.78 | |||
| Total Risk Alpha | 3.05 | |||
| Sortino Ratio | 0.9396 | |||
| Treynor Ratio | (1.28) | |||
| Maximum Drawdown | 230.06 | |||
| Value At Risk | (3.52) | |||
| Potential Upside | 5.14 | |||
| Downside Variance | 15.5 | |||
| Semi Variance | 4.14 | |||
| Expected Short fall | (9.24) | |||
| Skewness | 7.88 | |||
| Kurtosis | 63.34 |
Consider Poseida Therapeutics' intraday indicators
Poseida Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Poseida Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Poseida Therapeutics Corporate Filings
| 15th of January 2025 Other Reports | ViewVerify | |
| 13th of January 2025 Other Reports | ViewVerify | |
F4 | 10th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 8th of January 2025 Other Reports | ViewVerify |
Poseida Stock media impact
Far too much social signal, news, headlines, and media speculation about Poseida Therapeutics that are available to investors today. That information is available publicly through Poseida media outlets and privately through word of mouth or via Poseida internal channels. However, regardless of the origin, that massive amount of Poseida data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Poseida Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Poseida Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Poseida Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Poseida Therapeutics alpha.
Poseida Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Poseida Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
View Poseida Therapeutics Related Equities
| Risk & Return | Correlation |
Poseida Therapeutics Corporate Management
| Loren Wagner | Senior Operations | Profile | |
| Sarah Thailing | Senior IR | Profile | |
| JD Esq | Chief Counsel | Profile | |
| Johanna CPA | Chief Officer | Profile | |
| Kristin Martin | Chief Officer | Profile | |
| Alexander Chapman | Senior Communications | Profile | |
| Karen MBA | Senior Development | Profile |
Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.